Compare medications

Max 4 meds. Sources include DailyMed labels; verify against official labeling. Last reviewed shown per row. On small screens the table defaults to a compact view—use “Show all columns” to view everything (scroll horizontally). Visit individual drug pages for narratives, printable summaries, and therapeutic drug monitoring notes.

Add up to 4 medications

0/4 selected

Browse catalog

Oral Antipsychotics

Second Generation Antipsychotics (SGAs)

First Generation Antipsychotics (FGAs)

Long‑acting Injectable Antipsychotics (LAIs)

Mood Stabilizers

Adjunctive Medications

Ketamine & rapid-acting antidepressants (2)

Benzodiazepines (12)

Sleep & circadian agents (14)

ADHD & wakefulness agents (14)

Substance use treatment & harm reduction (11)

Metabolic & weight management (4)

Other adjunctive medications (17)

Compact view hides Indications, MOA, PK, TDM, Monitoring, and Reviewed.

Medication	Indications (label)	Dosing highlights	MOA	PK	TDM	Risk flags	Monitoring	LAI options	Last reviewed
eszopicloneAdjunctive therapyBrands: LUNESTA View labelExact	Insomnia (label). View labelExact	Typically taken immediately before bedtime, when able to remain in bed for a full night. Food can delay onset; when delayed onset is a concern, bedtime dosing is often separated from heavy meals. “Middle of the night” redosing is generally avoided.	Non-benzodiazepine hypnotic (“Z-drug”); GABA-A receptor positive allosteric modulator.	CYP3A4, CYP2E1 \| Single-dose mean 6 h	No	Sedation	Next-day impairment (driving, work, falls) after initiation and dose changes; dosing is adjusted or discontinued if safety is compromised. Complex sleep behaviors; when they occur, discontinuation is typical. Mood and suicidality in patients with depression or serious mental illness. If continued beyond a brief course, taper attempts and CBT-I reinforcement to reduce rebound insomnia.	No	2025-12-28
zolpidemAdjunctive therapyBrands: AMBIEN, AMBIEN CR View labelExact	Insomnia (label). View labelExact	Take immediately before bedtime, only when able to remain in bed for a full night. Food (especially high-fat meals) can delay onset; when rapid sleep onset is the goal, avoid taking with or immediately after a heavy meal.	Non-benzodiazepine hypnotic (“Z-drug”); GABA-A receptor positive allosteric modulator.	CYP3A4 \| Single-dose mean 2.5 h; Single-dose range 1.4–4.5 h	No	Sedation	Assess next-day impairment (driving, work, falls) after initiation and dose changes; lower the dose or stop if safety is compromised. Screen for complex sleep behaviors and discontinue immediately if they occur. Reassess for untreated sleep apnea, substance use, and mood episodes when insomnia persists rather than escalating hypnotics. If continued beyond a brief course, plan taper attempts and reinforce CBT-I to reduce rebound insomnia.	No	2025-12-28
doxepinAdjunctive therapyBrands: Sinequan, Silenor View labelExact	Depression and anxiety; low-dose formulation approved for insomnia. View labelExact	Depression/anxiety: typical start is 25–50 mg at bedtime; titrate by 25–50 mg every 3–4 days to 75–150 mg/day (single HS dose or divided BID). Max 300 mg/day inpatient with ECG monitoring.	Tricyclic antidepressant; strong antihistamine with serotonin and norepinephrine reuptake inhibition.	CYP2D6, CYP2C19 \| Single-dose mean 28 h; Steady-state mean 31 h	150–250 ng/mL	Weight Sedation QTc	Sedation, next-day impairment, and falls risk (especially in older adults); driving and occupational safety are often reassessed after dose changes. Orthostatic vitals during titration and when combined with other hypotensive medications; hydration and slow position changes are commonly emphasized. Anticholinergic burden (constipation, urinary retention, confusion); bowel regimen planning and avoiding additive anticholinergic polypharmacy are common considerations when feasible. ECG monitoring for patients with cardiac disease, electrolyte abnormalities, or higher antidepressant doses; repeat ECGs are often considered when adding other QT-active agents. Therapeutic drug monitoring can be helpful in higher-dose depression regimens, drug interactions (CYP2D6/2C19 inhibitors), unexpected nonresponse, or suspected toxicity. Mood activation (mania/hypomania) in bipolar-spectrum illness and suicidal thinking during initiation; coordination via the bipolar disorder hub can support planning.	No	2025-12-29
trazodoneAdjunctive therapyBrands: DESYREL, OLEPTRO View labelExact	Major depressive disorder (label); commonly used off label for insomnia. View labelExact	Insomnia (off label): start 25–50 mg at bedtime; typical 50–150 mg nightly based on tolerability; reassess frequently and avoid open-ended dose escalation.	Serotonin antagonist and reuptake inhibitor (SARI); 5-HT2 antagonism with weak SERT inhibition plus H1/α1 effects.	CYP3A4 \| Single-dose mean 7 h; Single-dose range 5–13 h	No	Sedation QTc	Monitor orthostatic symptoms and falls risk during initiation and after dose increases, especially in older adults or those on antihypertensives. Reassess mood and suicidality during antidepressant initiation and titration; ensure the dose matches the target (sleep vs depression). Review QT-risk co-medications and consider ECG/electrolytes when risk factors stack. If used primarily for insomnia, document a stop plan and reassess regularly rather than continuing indefinitely.	No	2025-12-28

Compare tool FAQ

How many medications can I compare at once?

You can line up to four medications at a time. Use the search box to add or remove drugs, then press “Compare” to refresh the table.

Where does the comparison data come from?

Most fields are generated from our curated facts + per-drug profiles. DailyMed label links come from source metadata, and LAI options come from our LAI catalog.

Can I save or share a comparison?

Yes. The Share button copies a link you can send to teammates, and we store your most recent selection so you can restore it next time you visit.